Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2002

View Archived Issues

Synaptica and Maybridge enter hit-to-lead optimization collaboration

Novel PDE3 and/or PDE4 inhibitors in Altana development pipeline

Novel compounds for pain and other disorders covered by Gruenenthal patent

Novel antibacterial oxazolidinones under study at Ortho-McNeil

Schering AG presents GnRH antagonists for use in infertility, contraception, etc.

Novel inhibitors of neutral sphingomyelinase in early development at Ono

Otsuka claims new adenosine A3 modulators and their use in glaucoma

Aventis presents new upregulators of eNOS expression

Protein Design Labs to evaluate two Arius anticancer antibodies

Arius and Xerion form colorectal cancer collaboration

Transition Therapeutics' INT enters clinical testing in U.K.

First E.U. trial of DTI-015 cleared to begin in U.K.

Cell Genesys reacquires full commercial rights to GVAX lung cancer vaccines

Highly potent and selective nAChR antagonist related to epibatidine reported in literature

Diaminopyrimidine DHFR inhibitor with promising antibacterial activity

Protection against cisplatin nephrotoxicity in rodents treated with BGP-15

Janssen-Ortho updates safety information for Risperdal in elderly dementia patients

Animal studies demonstrate sustained cocaine-like discriminative stimulus effects of RTI-113

Discovery and CollaGenex team up to develop novel treatments for respiratory diseases

Prous Science invites you to one of the first multipoint "megaconferences" in respiratory medicine

Inhale and Celltech enter licensing, manufacturing and supply agreement for three PEGylated products

Liver histology results for Innogenetics' E1 therapeutic vaccine for HCV

Copaxone approved for seven days room temperature storage in Europe

Centocor expands research and development to focus on immune-mediated inflammatory disorders

PDE5 inhibitor T-1032 effective in hamster model of chronic heart failure

Novartis files sNDA for Zometa showing long-term benefit

Helix to acquire minority interest in Sensium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.